Quick answer: Participants reported hair loss in tirzepatide weight-management trials, and the current U.S. Zepbound prescribing information lists it. In pooled placebo-controlled studies, the label reports hair loss in 1% of placebo participants and 5%, 4%, and 5% of participants in the 5 mg, 10 mg, and 15 mg tirzepatide groups. These trial observations do not prove the medicine caused each case or predict an individual outcome.
More broadly, this article summarizes evidence for research literacy. It is not personal medical advice, diagnosis, or treatment guidance. It does not apply to unapproved research products or establish their identity or safety.
What the current U.S. label reports
The FDA-approved Zepbound prescribing information lists hair loss among adverse reactions that researchers recorded in clinical trials. In the pooled weight-reduction and long-term maintenance trials, the table reports 1% with placebo, compared with 5% at 5 mg, 4% at 10 mg, and 5% at 15 mg. Additionally, the label reports that hair loss was more frequent among female than male participants in both treatment and placebo groups: 7.1% versus 0.5% with Zepbound, and 1.3% versus 0% with placebo.
For context, these are group-level trial percentages from the population and trial design described in the label. They should not be read as a prediction for any one person, as a comparison across every tirzepatide product, or as proof of a simple dose-response relationship.
Does the evidence prove tirzepatide directly causes hair loss?
Still, no single table can establish the cause of every reported event. The current label links hair-loss adverse reactions with weight reduction. Even so, that association is relevant, but it does not determine the mechanism for an individual case. For example, timing, amount and speed of weight change, nutrition, health conditions, other medicines, and baseline hair disorders can complicate interpretation.
A 2026 systematic review describes an emerging evidence base across GLP-1 receptor agonists, including tirzepatide, while emphasizing that more prospective studies are needed to clarify causality and vulnerable groups. By comparison, observational reports and trial adverse-event tables answer different questions; they should not be treated as interchangeable proof.
How to interpret the trial percentages
Reported events are not the same as confirmed diagnoses
Adverse-event tables summarize events that research teams recorded under a trial protocol. However, they do not necessarily identify one biological cause, establish a specific hair-loss diagnosis, or show how the event will progress after a trial ends.
Placebo comparisons add context, but not certainty
For context, the placebo group provides a reference for events occurring during the same research period. As a result, the difference between groups can help identify a signal, but trial data still have limits: researchers enroll selected populations, set the follow-up period, and classify events in ways that may not match a dermatology examination.
Sex-specific percentages require their own denominator
The label reports higher percentages among women than men in both treatment and placebo groups. However, those figures are subgroup summaries; they do not explain why the difference occurred and should not be generalized beyond the trials.
What researchers still need to learn
In addition, further prospective research can help separate possible medication effects from weight-loss-related changes and other contributors. In practice, useful studies would define hair-loss outcomes consistently, document timing and severity, collect relevant health and nutrition information, and follow participants long enough to understand patterns. The available sources do not justify a claim that every reported case is permanent or that a specific intervention will prevent it.
Questions readers ask about tirzepatide and hair loss
Is hair loss listed for Zepbound?
Yes. Specifically, the current U.S. prescribing information lists hair loss among adverse reactions in its pooled clinical-trial table.
Was hair loss more common with tirzepatide than placebo in those trials?
In these studies, the pooled table reports 4% to 5% across tirzepatide groups and 1% with placebo. Furthermore, the label notes that these events were associated with weight reduction; the percentages do not establish individual causation.
Does the label say hair loss is permanent?
In short, the trial table does not establish whether an individual event is temporary or permanent. It reports events recorded during the studies.
Do these findings apply to research-use-only vials?
No. The label describes an FDA-approved medicine studied in defined trials. It does not verify an unapproved product, research-use-only vial, or batch sold elsewhere.
References
- U.S. National Library of Medicine, DailyMed. Zepbound current prescribing information. Section 6.1, clinical-trial experience. Accessed October 10, 2026.
- Gupta AK, et al. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. 2026.
- U.S. FDA. Zepbound prescribing information. Drugs@FDA.
Research-literacy summary, not medical advice. Consult a qualified health professional for questions about a prescribed medicine or new symptoms. Reviewed October 10, 2026.
